NASDAQ:HROW Harrow Health (HROW) Stock Forecast, Price & News $19.56 +0.05 (+0.26%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$19.08▼$19.7150-Day Range$18.86▼$28.0852-Week Range$6.00▼$28.25Volume220,342 shsAverage Volume626,787 shsMarket Capitalization$589.15 millionP/E RatioN/ADividend YieldN/APrice Target$30.47 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Harrow Health MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside55.8% Upside$30.47 Price TargetShort InterestBearish7.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth1,450.00%From $0.06 to $0.93 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.17 out of 5 starsMedical Sector364th out of 983 stocksPharmaceutical Preparations Industry173rd out of 486 stocks 3.5 Analyst's Opinion Consensus RatingHarrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.47, Harrow Health has a forecasted upside of 55.8% from its current price of $19.56.Amount of Analyst CoverageHarrow Health has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.34% of the outstanding shares of Harrow Health have been sold short.Short Interest Ratio / Days to CoverHarrow Health has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Harrow Health has recently increased by 1.38%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHarrow Health does not currently pay a dividend.Dividend GrowthHarrow Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 2.6 News and Social Media Coverage News SentimentHarrow Health has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Harrow Health this week, compared to 3 articles on an average week.Search InterestOnly 33 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat Follows7 people have added Harrow Health to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow Health insiders have not sold or bought any company stock.Percentage Held by Insiders14.26% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.47% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Harrow Health are expected to grow by 1,450.00% in the coming year, from $0.06 to $0.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow Health is -30.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow Health is -30.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow Health has a P/B Ratio of 27.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harrow Health (NASDAQ:HROW) StockHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HROW Stock News HeadlinesMay 27, 2023 | americanbankingnews.comHarrow Health (NASDAQ:HROW) Shares Down 9% May 17, 2023 | americanbankingnews.comHarrow Health (NASDAQ:HROW) Trading Down 5%June 4, 2023 | Altimetry (Ad)Surprising "Twist" Hands Biden Landslide Re-election?This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.May 17, 2023 | finance.yahoo.comHarrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023May 17, 2023 | americanbankingnews.comB. Riley Weighs in on Harrow Health, Inc.'s Q2 2023 Earnings (NASDAQ:HROW)May 16, 2023 | finance.yahoo.comHarrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call TranscriptMay 13, 2023 | americanbankingnews.comHarrow Health (NASDAQ:HROW) Given New $32.40 Price Target at LADENBURG THALM/SH SHMay 12, 2023 | markets.businessinsider.comLake Street Keeps Their Buy Rating on Harrow Health (HROW)June 4, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 12, 2023 | msn.comHarrow Health falls 23% despite Q1 revenue beatMay 12, 2023 | finance.yahoo.comWhy Shares of Harrow Health Are Slumping FridayMay 12, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Harrow Health (HROW)May 12, 2023 | americanbankingnews.comHarrow Health (NASDAQ:HROW) Hits New 52-Week High at $28.25May 11, 2023 | seekingalpha.comHarrow Health, Inc. (HROW) Q1 2023 Earnings Call TranscriptMay 11, 2023 | msn.comRecap: Harrow Health Q1 EarningsMay 10, 2023 | msn.comEarnings Preview For Harrow HealthMay 9, 2023 | americanbankingnews.comHarrow Health (HROW) to Release Quarterly Earnings on ThursdayMay 9, 2023 | americanbankingnews.comHarrow Health, Inc. Expected to Earn Q1 2023 Earnings of ($0.06) Per Share (NASDAQ:HROW)May 8, 2023 | msn.comHarrow Health (HROW) to Report Q1 Earnings: What's in the Offing?May 5, 2023 | americanbankingnews.comHarrow Health's (HROW) Buy Rating Reaffirmed at B. RileyMay 4, 2023 | finance.yahoo.comHarrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingMay 4, 2023 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) versus Harrow Health (NASDAQ:HROW) Head to Head AnalysisMay 3, 2023 | americanbankingnews.comHarrow Health, Inc. (NASDAQ:HROW) Short Interest UpdateMay 1, 2023 | finance.yahoo.comHere's Why Momentum in Harrow (HROW) Should Keep goingApril 28, 2023 | finance.yahoo.comZacks.com featured highlights Harrow Health and Disc Medicine OpcoApril 27, 2023 | finance.yahoo.com2 Stocks in Focus as Analysts Initiate CoverageApril 24, 2023 | nasdaq.comHarrow Health and CDW have been highlighted as Zacks Bull and Bear of the DaySee More Headlines HROW Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Company Calendar Last Earnings3/23/2023Today6/03/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.47 High Stock Price Forecast$37.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+55.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E Ratio326.00 P/E GrowthN/ANet Income$-14,090,000.00 Net Margins-19.76% Pretax Margin-19.99% Return on Equity-1.57% Return on Assets-0.15% Debt Debt-to-Equity Ratio7.84 Current Ratio2.92 Quick Ratio2.41 Sales & Book Value Annual Sales$88.60 million Price / Sales6.65 Cash Flow$0.22 per share Price / Cash Flow88.23 Book Value$0.71 per share Price / Book27.55Miscellaneous Outstanding Shares30,120,000Free Float25,827,000Market Cap$589.15 million OptionableOptionable Beta0.20 Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsSeres TherapeuticsNASDAQ:MCRB2seventy bioNASDAQ:TSVTTerns PharmaceuticalsNASDAQ:TERNTyra BiosciencesNASDAQ:TYRAEdgewise TherapeuticsNASDAQ:EWTXView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCSold 60,216 shares on 6/1/2023Ownership: 0.145%Ameriprise Financial Inc.Sold 25,509 shares on 5/22/2023Ownership: 0.325%JPMorgan Chase & Co.Sold 8,937 shares on 5/18/2023Ownership: 0.179%Westside Investment Management Inc.Sold 39,230 shares on 5/17/2023Ownership: 0.500%Balyasny Asset Management L.P.Sold 4,376 shares on 5/16/2023Ownership: 0.034%View All Insider TransactionsView All Institutional Transactions HROW Stock - Frequently Asked Questions Should I buy or sell Harrow Health stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow Health's stock price forecast for 2023? 2 brokers have issued twelve-month price targets for Harrow Health's stock. Their HROW share price forecasts range from $22.00 to $37.00. On average, they expect the company's share price to reach $30.47 in the next year. This suggests a possible upside of 55.8% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2023? Harrow Health's stock was trading at $14.76 at the start of the year. Since then, HROW stock has increased by 32.5% and is now trading at $19.56. View the best growth stocks for 2023 here. When is Harrow Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our HROW earnings forecast. How were Harrow Health's earnings last quarter? Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings data on Thursday, March, 23rd. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.22. The firm had revenue of $20.33 million for the quarter, compared to analyst estimates of $23.26 million. Harrow Health had a negative net margin of 19.76% and a negative trailing twelve-month return on equity of 1.57%. What ETFs hold Harrow Health's stock? ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS), Hartford Multifactor Small Cap ETF (ROSC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and What guidance has Harrow Health issued on next quarter's earnings? Harrow Health issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$143.00 million, compared to the consensus revenue estimate of $137.06 million. What other stocks do shareholders of Harrow Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). What is Harrow Health's stock symbol? Harrow Health trades on the NASDAQ under the ticker symbol "HROW." Who are Harrow Health's major shareholders? Harrow Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Braidwell LP (4.82%), Private Capital Management LLC (3.87%), Portolan Capital Management LLC (3.56%), Renaissance Technologies LLC (3.20%), Assenagon Asset Management S.A. (2.68%) and BlackRock Inc. (1.65%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow Health? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harrow Health's stock price today? One share of HROW stock can currently be purchased for approximately $19.56. How much money does Harrow Health make? Harrow Health (NASDAQ:HROW) has a market capitalization of $589.15 million and generates $88.60 million in revenue each year. The company earns $-14,090,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. How many employees does Harrow Health have? The company employs 182 workers across the globe. How can I contact Harrow Health? Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745. This page (NASDAQ:HROW) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.